Abstract
Investigation of a Symploca sp. from Papua New Guinea has led to the isolation of symplocamide A (1), a potent cancer cell cytotoxin, which also inhibits serine proteases with a 200-fold greater inhibition of chymotrypsin over trypsin. The complete stereostructure of symplocamide A was determined by detailed NMR and MS analysis as well as chiral HPLC analysis of the component amino acid residues. The presence of several unusual structural features in symplocamide A provides new insights into the pharmacophore model for protease selectivity in this drug class and may underlie the potent cytotoxicity of this compound to H-460 lung cancer cells (IC50=40 nM) as well as neuro-2a neuroblastoma cells (IC50=29 nM).
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / isolation & purification*
-
Antineoplastic Agents / pharmacology*
-
Chymotrypsin / antagonists & inhibitors*
-
Cyanobacteria / chemistry*
-
Cytotoxins / chemistry
-
Cytotoxins / isolation & purification*
-
Cytotoxins / pharmacology*
-
Depsipeptides / chemistry
-
Depsipeptides / isolation & purification*
-
Depsipeptides / pharmacology*
-
Drug Screening Assays, Antitumor
-
Humans
-
Leishmania donovani / drug effects
-
Marine Toxins / chemistry
-
Marine Toxins / isolation & purification*
-
Marine Toxins / pharmacology*
-
Molecular Structure
-
Papua New Guinea
-
Plasmodium falciparum / drug effects
-
Trypanosoma cruzi / drug effects
Substances
-
Antineoplastic Agents
-
Cytotoxins
-
Depsipeptides
-
Marine Toxins
-
symplocamide A
-
Chymotrypsin